ArticlePloS one2014
Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey.Journal of clinical medicine · 2026Article
- Knowledge, Use, and Barriers in Dyslipidemia Management: A Cross-Sectional Survey of Clinicians.Journal of clinical medicine · 2026Article
- Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants: A Critical Review From the Middle East.JACC. Asia · 2025Review
- Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Lipid-lowering prescription patterns after a non-fatal acute coronary syndrome: A retrospective cohort study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.Advances in therapy · 2025Review
- Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.Reviews in cardiovascular medicine · 2024Review
- Article
- Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.Cardiology and therapy · 2023Article
- The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know.Current atherosclerosis reports · 2023Review
- Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia.Saudi medical journal · 2023Article
- The burden of metabolic risk factors in North Africa and the Middle East, 1990-2019: findings from the Global Burden of Disease Study.EClinicalMedicine · 2023Article
- Observational
- Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.Journal of diabetes · 2022Review
- Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II.Clinical cardiology · 2021 · on this mapObservational
- Review
- Genome-wide landscape establishes novel association signals for metabolic traits in the Arab population.Human genetics · 2021Article
- Improvement initiative in LDL-C management in Saudi Arabia: A call to action.International journal of cardiology. Heart & vasculature · 2020Review
- Effectiveness of an audit programme for dyslipidaemia management in a primary care setting in Macau: a quality improvement study.Family medicine and community health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore, the objective of this study was to assess the frequency of lipid abnormalities in patients receiving chronic statin treatment.
methodsAs part of an international, cross-sectional, observational study, DYSIS-Middle East enrolled 2,182 patients in the United Arab Emirates (UAE), Saudi Arabia, Lebanon and Jordan. All patients were over 45 years of age and had been on statin treatment for at least three months. Data on demographics, lipid parameters and cardiovascular risk profile were recorded. Cardiovascular risk was defined according the guidelines of the European Society of Cardiology.
resultsThe majority of patients (82.6%) were classified as being at very high risk of cardiovascular events, and 61.8% of all patients did not attain LDL-C target levels. Low high-density lipoprotein cholesterol levels and elevated triglyceride levels were noted in 55.5% and 48.5% of patients, respectively. Multivariate logistical regression modeling indicated that factors independently associated with LDL-C levels not being at goal were lifestyle choices, diabetes mellitus, ischemic heart disease, and blood pressure ≥ 140/90 mmHg.
conclusionsAlmost two-thirds of statin-treated patients in the United Arab Emirates, Saudi Arabia, Lebanon and Jordan had inadequately controlled lipid levels. More comprehensive surveillance, awareness and treatment regimens, as well as modification of lifestyle choices, is necessary to halt the rise in cardiovascular disease-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.